Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib

por Huijberts, Sanne C. F. A., Boelens, Mirjam C., Bernards, Rene, Opdam, Frans L.
Publicado 2020

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorecta...

por Van Cutsem, Eric, Huijberts, Sanne, Grothey, Axel, Yaeger, Rona, Cuyle, Pieter-Jan, Elez, Elena, Fakih, Marwan, Montagut, Clara, Peeters, Marc, Yoshino, Takayuki, Wasan, Harpreet, Desai, Jayesh, Ciardiello, Fortunato, Gollerkeri, Ashwin, Christy-Bittel, Janna, Maharry, Kati, Sandor, Victor, Schellens, Jan H.M., Kopetz, Scott, Tabernero, Josep
Publicado 2019

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cance...

por van Geel, Robin M. J. M., van Brummelen, Emilie M. J., Eskens, Ferry A. L. M., Huijberts, Sanne C. F. A., de Vos, Filip Y. F. L., Lolkema, Martijn P. J. K., Devriese, Lot A., Opdam, Frans L., Marchetti, Serena, Steeghs, Neeltje, Monkhorst, Kim, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Beijnen, Jos H., Bernards, René, Schellens, Jan H. M.
Publicado 2020